CNS Pharmaceuticals, Inc.
83.0M
$4.50M
-0.15
$-35.75
No price alerts set. Add an alert to get notified!
-0.15
0.51
$-35.75
-350.48%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
CMND
Clearmind Medicine Inc.
|
$0.68 | 2.58% | -0.10 | $92,245 | 0.00 |
|
ENSC
Ensysce Biosciences, Inc.
|
$0.42 | 7.20% | -0.10 | $3.87M | 95,437.06 |
|
GRI
GRI Bio, Inc.
|
$2.26 | 3.67% | -0.09 | $203,020 | 0.01 |
|
KTTA
Pasithea Therapeutics Corp.
|
$0.85 | 0.67% | -0.29 | $6.30M | 0.00 |
|
NLSP
NLS Pharmaceutics AG
|
$2.91 | -12.61% | -0.70 | $919,601 | 0.00 |
|
OGEN
Oragenics, Inc.
|
$0.62 | -0.31% | -0.27 | $2.68M | 27.45 |
|
SILO
Silo Pharma, Inc.
|
$0.46 | 1.32% | -1.45 | $3.69M | 0.00 |
|
SNGX
Soligenix, Inc.
|
$0.35 | 0.00 | -0.31 | $3.56M | 0.07 |
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
$1.61 | -3.01% | -0.15 | $1.30M | 0.04 |
|
WINT
Windtree Therapeutics, Inc.
|
$0.02 | -15.25% | 0.00 | $674,176 | -1.11 |
* Peer stocks are selected based on market capitalization and sector
$34.80
$1.90
$0.00
0.00%
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
